Topical and systemic medications for the treatment of primary Sjögren's syndrome

Nature Reviews Rheumatology

Volumn 8, Issue 7, 2012, Pages 399-411

  Ramos Casals, Manuel ^a   Brito Zerón, Pilar ^a   Sisó Almirall, Antoni ^a   Bosch, Xavier ^a   Tzioufas, Athanasios G ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CARBOXYMETHYLCELLULOSE; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN A; DICLOFENAC; DIQUAFOSOL; FLUOROMETHOLONE; GLUCOCORTICOID; HYALURONIC ACID; HYDROXYCHLOROQUINE; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; LEFLUNOMIDE; LOTEPREDNOL; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MIZORIBINE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PILOCARPINE; PIROXICAM; PLACEBO; PREDNISOLONE; PREDNISONE; SALIVA SUBSTITUTE; UNINDEXED DRUG;

APPETITE; ARTHRALGIA; AUTOIMMUNE DISEASE; BLURRED VISION; CANDIDIASIS; CATARACT; CLINICAL FEATURE; CORNEA DISEASE; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; DRY SKIN; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; EYE BURNING; EYE DISEASE; EYE TOXICITY; FATIGUE; FLUSHING; GINGIVA BLEEDING; HUMAN; INTRAOCULAR PRESSURE; JOINT SWELLING; KERATITIS; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; MOUTH HYGIENE; MOUTH INFECTION; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PERFORATING EYE INJURY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCLERA DISEASE; SIDE EFFECT; SJOEGREN SYNDROME; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; TOOTH PLAQUE; ULCER; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VAGINAL DRYNESS; WEIGHT GAIN; XEROPHTHALMIA; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; KERATOCONJUNCTIVITIS SICCA; MALE; OPHTHALMIC SOLUTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALIVA, ARTIFICIAL; SALIVATION; SJOGREN'S SYNDROME; TREATMENT OUTCOME; XEROSTOMIA;

EID: 84863497528     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.53     Document Type: Review

References (123)

1. Fox, R. I. Sjögren's syndrome. Lancet 366, 321-331 (2005).
2. Kassan, S. S. & Moutsopoulos, H. M. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch. Intern. Med. 164, 1275-1284 (2004).
3. Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A. & Bosch, X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 304, 452-460 (2010).
4. Alpöz, E. et al. The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, crossover study. Clin. Oral Investig. 12, 165-172 (2008).
5. Alves, M. B., Motta, A. C., Messina, W. C. & Migliari, D. A. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int. 35, 392-396 (2004).
6. Aagaard, A., Godiksen, S., Teglers, P. T., Schiødt, M. & Glenert, U. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J. Oral Pathol. Med. 21, 376-380 (1992).
7. Johansson G. et al. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation. Gerodontology 18, 87-94 (2001).
8. Rhodus, N. L. & Bereuter, J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J. Otolaryngol. 29, 28-34 (2000).
9. van der Reijden, W. A., van der Kwaak, H., Vissink, A., Veerman, E. C. & Amerongen, A. V. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum. 39, 57-63 (1996).
10. Visch, L. L., Gravenmade, E. J., Schaub, R. M., Van Putten, W. L. & Vissink, A. A double-blind crossover trial of CMC-and mucin-containing saliva substitutes. Int. J. Oral Maxillofac. Surg. 15, 395-400 (1986).
11. Aragona, P., Di Stefano, G., Ferreri, F., Spinella, R. & Stilo, A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br. J. Ophthalmol. 86, 879-884 (2002).
12. Aragona, P., Papa, V., Micali, A., Santocono, M. & Milazzo, G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br. J. Ophthalmol. 86, 181-184 (2002).
13. Brignole, F., Pisella, P. J., Dupas, B., Baeyens, V. & Baudouin, C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 243, 531-538 (2005).
14. Condon, P. I. et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br. J. Ophthalmol. 83, 1121-1124 (1999).
15. McDonald, C. C., Kaye, S. B., Figueiredo, F. C., Macintosh, G. & Lockett, C. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond.) 16, 601-607 (2002).
16. Toda, I., Shinozaki, N. & Tsubota, K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome. Cornea 15, 120-128 (1996).
17. Aragona, P., Stilo, A., Ferreri, F. & Mobrici, M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients. Eye (Lond.) 19, 535-539 (2005).
18. Avisar, R., Robinson, A., Appel, I., Yassur, Y. & Weinberger, D. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea 19, 145-147 (2000).
19. Guidera, A. C., Luchs, J. I. & Udell, I. J. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 108, 936-944 (2001).
20. Avunduk, A. M., Avunduk, M. C., Varnell, E. D. & Kaufman, H. E. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol. 136, 593-602 (2003).
21. Marsh, P. & Pflugfelder, S. C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 106, 811-816 (1999).
22. Pflugfelder, S. C. et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol. 138, 444-457 (2004).
23. Hong, S., Kim, T., Chung, S. H., Kim, E. K. & Seo, K. Y. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. J. Ocul. Pharmacol. Ther. 23, 78-82 (2007).
24. Dastjerdi, M. H., Hamrah, P. & Dana, R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28, 1091-1096 (2009).
25. Gündüz, K. & Ozdemir, O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome. Acta. Ophthalmol. (Copenh.) 72, 438-442 (1994).
26. Kunert, K. S., Tisdale, A. S., Stern, M. E., Smith, J. A. & Gipson, I. K. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch. Ophthalmol. 118, 1489-1496 (2000).
27. Roberts, C. W., Carniglia, P. E. & Brazzo, B. G. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 26, 805-809 (2007).
28. Sall, K. N., Cohen, S. M., Christensen, M. T. & Stein, J. M. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens 32, 21-26 (2006).
29. Stevenson, D., Tauber, J. & Reis, B. L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107, 967-974 (2000).
30. Toker, E. & Asfuroglu, E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea 29, 133-140 (2010).
31. Perry, H. D. et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch. Ophthalmol. 126, 1046-1050 (2008).
32. Sall, K., Stevenson, O. D., Mundorf, T. K. & Reis, B. L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107, 631-639 (2000).
33. Kim, E. C., Choi, J. S. & Joo, C. K. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am. J. Ophthalmol. 147, 206-213 (2009).
34. Barber, L. D., Pflugfelder, S. C., Tauber, J. & Foulks, G. N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112, 1790-1794 (2005).
35. Tauber, J. et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23, 784-792 (2004).
36. Schiødt, M., Oxholm, P. & Jacobsen, A. Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem. Scand. J. Rheumatol. Suppl. 61, 250-252 (1986).
37. Kriegbaum, N. J., von Linstow, M., Oxholm, P. & Prause, J. U. A follow-up study of the progress of keratoconjunctivitis sicca and response to treatment in primary Sjögren's syndrome. Scand. J. Rheumatol. 18, 193-196 (1989).
38. Walters, M. T., Rubin, C. E., Keightley, S. J., Ward, C. D. & Cawley, M. I. A double-blind, crossover, study of oral N-acetylcysteine in Sjögren's syndrome. Scand. J. Rheumatol. Suppl. 61, 253-258 (1986).
39. Aframian, D. J. et al. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 13, 88-92 (2007).
40. Aragona, P., Di Pietro, R., Spinella, R. & Mobrici, M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjögren's syndrome. Br. J. Ophthalmol. 90, 166-170 (2006).
41. Gibson, J., Halliday, J. A., Ewert, K. & Robertson, S. A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome. Br. Dent. J. 202, E17 (2007).
42. Papas, A. S. et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J. Clin. Rheumatol. 10, 169-177 (2004).
43. Rhodus, N. L., Liljemark, W., Bloomquist, C. & Bereuter, J. Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study. Quintessence Int. 29, 705-710 (1998).
44. Peluso, G. et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum. 56, 2216-2222 (2007).
45. Rhodus, N. L. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. Oral Dis. 3, 93-98 (1997).
46. Rosas, J. et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features. Rheumatology (Oxford) 41, 670-675 (2002).
47. Tsifetaki, N. et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann. Rheum. Dis. 62, 1204-1207 (2003).
48. Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. 159, 174-181 (1999).
49. Wu, C. H. et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan\a double-blind, placebo-controlled trial. J. Formos. Med. Assoc. 105, 796-803 (2006).
50. Fife, R. S. et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch. Intern. Med. 162, 1293-1300 (2002).
51. Komai, K. et al. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment. Mod. Rheumatol. 19, 416-419 (2009).
52. Leung, K. C. et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin. Rheumatol. 27, 429-436 (2008).
53. Ono, M. et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am. J. Ophthalmol. 138, 6-17 (2004).
54. Petrone, D. et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 46, 748-754 (2002).
55. Suzuki, K. et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology 74, 100-105 (2005).
56. Takagi, Y., Katayama, I., Tashiro, S. & Nakamura, T. Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome. J. Rheumatol. 35, 2289-2291 (2008).
57. Yamada, H. et al. Efficacy prediction of cevimeline in patients with Sjögren's syndrome. Clin. Rheumatol. 26, 1320-1327 (2007).
58. Izumi, M. et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome. Ann. Rheum. Dis. 57, 464-469 (1998).
59. Miyawaki, S., Nishiyama, S. & Matoba, K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern. Med. 38, 938-943 (1999).
60. Fox, P. C. et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin. Exp. Rheumatol. 11, 149-156 (1993).
61. Pijpe, J. et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann. Rheum. Dis. 66, 107-112 (2007).
62. Ramos-Casals, M. et al. High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. J. Rheumatol. 34, 754-761 (2007).
63. Kruize, A. A. et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann. Rheum. Dis. 52, 360-364 (1993).
64. Tishler, M., Yaron, I., Shirazi, I. & Yaron, M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis. 58, 253-256 (1999).
65. Rihl, M., Ulbricht, K., Schmidt, R. E. & Witte, T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome. Rheumatology (Oxford) 48, 796-799 (2009).
66. Fox, R. I. et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am. J. Med. 85, 62-67 (1988).
67. Fox, R. I., Dixon, R., Guarrasi, V. & Krubel, S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 (Suppl. 1), S31-S36 (1996).
68. Cankaya, H. et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 110, 62-67 (2010).
69. Yavuz, S., Asfuroglu, E., Bicakcigil, M. & Toker, E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren's syndrome. Rheumatol. Int. 31, 1045-1049 (2011).
70. Drosos, A. A., Skopouli, F. N., Galanopoulou, V. K., Kitridou, R. C. & Moutsopoulos, H. M. Cyclosporin A therapy in patients with primary Sjögren's syndrome: results at one year. Scand. J. Rheumatol Suppl. 61, 246-249 (1986).
71. Skopouli, F. N., Jagiello, P., Tsifetaki, N. & Moutsopoulos, H. M. Methotrexate in primary Sjögren's syndrome. Clin. Exp. Rheumatol. 14, 555-558 (1996).
72. van Woerkom, J. M. et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann. Rheum. Dis. 66, 1026-1032 (2007).
73. Willeke, P. et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Ar thritis Res. Ther. 9, R115 (2007).
74. Price, E. J., Rigby, S. P., Clancy, U. & Venables, P. J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J. Rheumatol.25, 896-899 (1998).
75. ter Borg, E. J. et al. Treatment of primary Sjögren's syndrome with d-penicillamine: a pilot study. Neth. J. Med. 60, 402-406 (2002).
76. Pillemer, S. R. et al. Prominent adverse effects of thalidomide in primary Sjögren's syndrome. Arthritis Rheum. 51, 505-506 (2004).
77. Nakayamada, S. et al. Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Mod. Rheumatol. 17, 464-469 (2007).
78. Nakayamada, S. et al. Usefulness of initial histological features for stratifying Sjögren's syndrome responders to mizoribine therapy. Rheumatology (Oxford) 48, 1279-1282 (2009).
79. Sugai, S. et al. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. Mod. Rheumatol. 19, 114-124 (2009).
80. Seitsalo, H. et al. Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study. J. Negat. Results Biomed. 6, 11 (2007).
81. Steinfeld, S. D., Demols, P., Van Vooren, J. P., Cogan, E. & Appelboom, T. Zidovudine in primary Sjögren's syndrome. Rheumatology (Oxford) 38, 814-817 (1999).
82. Pillemer, S. R. et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis Rheum. 51, 601-604 (2004).
83. Hartkamp, A. et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Ann. Rheum. Dis. 67, 91-97 (2008).
84. Forsbladd'Elia, H., Carlsten, H., Labrie, F., Konttinen, Y. T. & Ohlsson, C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J. Clin. Endocrinol. Metab. 94, 2044-2051 (2009).
85. 1 tear content in Sjögren's syndrome patients. Invest. Ophthalmol. Vis. Sci. 46, 4474-4479 (2005).
86. Theander, E., Horrobin, D. F., Jacobsson, L. T. & Manthorpe, R. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome. Scand. J. Rheumatol. 31, 72-79 (2002).
87. Oxholm, P., Manthorpe, R., Prause, J. U. & Horrobin, D. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. Scand. J. Rheumatol. 15, 103-108 (1986).
88. Kasama, T. et al. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. Mod. Rheumatol. 18, 455-459 (2008).
89. Cummins, M. J., Papas, A., Kammer, G. M. & Fox, P. C. Treatment of primary Sjögren's syndrome with low-dose human interferon α administered by the oromucosal route: combined phase III results. Arthritis Rheum. 49, 585-593 (2003).
90. Shiozawa, S., Tanaka, Y. & Shiozawa, K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren's syndrome. J. Interferon Cytokine Res. 18, 255-262 (1998).
91. Khurshudian, A. V. A pilot study to test the efficacy of oral administration of interferon-α lozenges to patients with Sjögren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95, 38-44 (2003).
92. Ferraccioli, G. F. et al. Interferon α2 (IFN α2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin. Exp. Rheumatol. 14, 367-371 (1996).
93. Steinfeld, S. D., Demols, P., Salmon, I., Kiss, R. & Appelboom, T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 44, 2371-2375 (2001).
94. Mariette, X. et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 50, 1270-1276 (2004).
95. Zandbelt, M. M. et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J. Rheumatol. 31, 96-101 (2004).
96. Sankar, V. et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50, 2240-2245 (2004).
97. Meijer, J. et al. Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960-968 (2010).
98. Dass, S. et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541-1544 (2008).
99. Devauchelle-Pensec, V. et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57, 310-317 (2007).
100. Pijpe, J. et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740-2750 (2005).
101. Seror, R. et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann. Rheum. Dis. 66, 351-357 (2007).
102. Gottenberg, J. E. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913-920 (2005).
103. Voulgarelis, M., Giannouli, S., Tzioufas, A. G. & Moutsopoulos, H. M. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 65, 1033-1037 (2006).
104. Mekinian, A. et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis. 71, 84-87 (2012).
105. Ramos-Casals, M. et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin. Exp. Rheumatol. 28, 468-476 (2010).
106. Steinfeld, S. D. et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res. Ther. 8, R129 (2006).
107. Vissink, A., Kallenberg, C. G. & Bootsma, H. Treatment approaches in primary Sjogren syndrome. JAMA 304, 2015-2016 (2010).
108. Yoon, K. C. et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am. J. Ophthalmol. 144, 86-92 (2007).
109. Noble, B. A. et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br. J. Ophthalmol. 88, 647-652 (2004).
110. Belenguer, R. et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome. Clin. Exp. Rheumatol. 23, 351-356 (2005).
111. Ostuni, P. et al. Fibromyalgia in Italian patients with primary Sjögren's syndrome. Joint Bone Spine. 69, 51-57 (2002).
112. Engel, P., Gómez-Puerta, J. A., Ramos-Casals, M., Lozano, F. & Bosch, X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol. Rev. 63, 127-156 (2011).
113. Mavragani, C. P. & Kassan, S. S. in Sjögren's Syndrome. Diagnosis and Therapeutics (eds Ramos-Casals, M., Stone, J. & Moutsopoulos, H. M.) 565-570 (Springer-Verlag, Berlin, 2012).
114. Brito-Zerón, P. & Ramos-Casals, M. Prognosis of patients with primary Sjögren's syndrome [Spanish]. Med. Clin. (Barc.) 130, 109-115 (2008).
115. Ramos-Casals, M., Brito-Zerón, P., Bové, A. & Sisó, A. in Autoimmune Diseases. Acute and Complex Situations (eds Khamashta, M. A. & Ramos-Casals, M.) 45-66 (Springer-Verlag, London, 2011).
116. Pollard, R. P. et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: a retrospective clinical study. J. Rheumatol. 38, 2198-2208 (2011).
117. Pijpe, J. et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 60, 3251-3256 (2009).
118. Jousse-Joulin, S. et al. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 1, 311-319 (2007).
119. Lavie, F. et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66, 700-703 (2007).
120. Strietzel, F. P. et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 63, 180-190 (2011).
121. Seror, R. et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index in primary Sjögren's syndrome. Ann. Rheum. Dis. 69, 1103-1109 (2010).
122. Seror, R. et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann. Rheum. Dis. 70, 968-972 (2011).
123. Harbour, R & Miller, J. A new system for grading recommendations in evidence based guidelines. BMJ 323, 334-336 (2001).